Welcome to our dedicated page for Erasca news (Ticker: ERAS), a resource for investors and traders seeking the latest updates and insights on Erasca stock.
Erasca, Inc. develops precision oncology therapies for cancers driven by the RAS/MAPK pathway. News on ERAS commonly centers on its RAS-targeting pipeline, including ERAS-0015, an investigational oral pan-RAS molecular glue evaluated in RAS-mutant solid tumors, and ERAS-4001, an oral pan-KRAS inhibitor for KRAS-mutant solid tumors.
Company updates frequently cover Phase 1 clinical data, dose-escalation results, trial collaborations and supply agreements, intellectual-property protection, development rights, public offering activity, financial results, and healthcare conference presentations. Recurring cancer settings in company disclosures include non-small cell lung cancer, pancreatic adenocarcinoma, colorectal cancer, and other RAS-mutant solid tumors.
Erasca (Nasdaq: ERAS) closed its previously announced upsized public offering of 36,142,857 common shares, including 4,714,285 shares from the underwriters’ full over‑allotment option, at $17.50 per share. Gross proceeds to Erasca were approximately $632.5 million before underwriting discounts, commissions, and expenses.
According to Erasca, all shares were issued by the company, and it plans to use the net proceeds, together with existing cash, cash equivalents, and marketable securities, to fund research and development of its oncology product candidates, other development programs, and for working capital and general corporate purposes. The offering was conducted under an effective shelf registration on Form S‑3, with J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI serving as joint book‑running managers.
Erasca (Nasdaq: ERAS) priced an upsized public offering of 31,428,572 common shares at $17.50 per share, for expected gross proceeds of about $550 million before fees and expenses. All shares are being sold by Erasca.
The company granted underwriters a 30-day option to buy up to 4,714,285 additional shares at the offering price, less underwriting discounts and commissions. The offering is expected to close on July 15, 2026, subject to customary conditions. According to Erasca, net proceeds plus existing cash will fund R&D, other development programs, and general corporate purposes.
Erasca (Nasdaq: ERAS) announced a proposed underwritten public offering of $500 million of its common stock, with all shares to be sold by the company. Erasca also plans to grant underwriters a 30-day option to purchase up to an additional $75 million of common stock.
According to Erasca, net proceeds, together with existing cash, cash equivalents, and marketable securities, are expected to fund research and development of its product candidates, other development programs, and general corporate purposes. J.P. Morgan, Morgan Stanley, Jefferies, and Evercore ISI are joint book-running managers. The offering will be made under an effective Form S-3 shelf registration statement.
Erasca (Nasdaq: ERAS) reported updated preliminary Phase 1 AURORAS-1 data for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors and outlined potentially registration-enabling plans in lung and pancreatic cancers.
At the recommended dose for expansion (RDE) of 32 mg QD, ERAS-0015 monotherapy showed a 57% uORR at 8 weeks (N=7) in second-line or later KRAS G12X pancreatic ductal adenocarcinoma, with most enrolled patients remaining on treatment across 24 mg and 32 mg doses and a median relative dose intensity of 100% at both doses. Safety remained generally consistent with prior disclosures, with mostly low-grade treatment-related adverse events, no dose-limiting toxicities, low rates of dose interruptions or reductions due to TRAEs, and no discontinuations due to TRAEs.
In metastatic colorectal cancer, the first dose-escalation cohort combining ERAS-0015 16 mg with the approved commercial dose of panitumumab reported no DLTs in four DLT-evaluable patients, enabling cohort clearance and ongoing backfill and dose escalation. According to Erasca, additional monotherapy and combination data are expected in the first half of 2027. The company plans to initiate a potentially registration-enabling trial in 2L+ NSCLC in H1 2027, a Phase 3 pivotal trial in first-line pancreatic cancer in 2027, and a Phase 3 pivotal trial in RAS-mutant NSCLC between H2 2027 and H1 2028.
Erasca (Nasdaq: ERAS), a clinical-stage precision oncology company targeting RAS/MAPK pathway-driven cancers, will participate in the Jefferies Global Healthcare Conference at the Marriott Marquis in New York.
Management will join a fireside chat on June 3, 2026 at 3:10 p.m. ET, with a live and archived webcast on Erasca.com/events.
Erasca (Nasdaq: ERAS) reported first quarter 2026 results and RAS-franchise progress. ERAS-0015 showed robust preliminary monotherapy responses in KRAS G12X NSCLC and PDAC with generally low-grade AEs, and expansion and combination cohorts began ahead of prior guidance. ERAS-4001 advanced in Phase 1 with US patent protection to June 2043.
Clinical collaborations were signed with Merck to combine ERAS-0015 with KEYTRUDA and with Tango for combination with vopimetostat. Cash, cash equivalents, and marketable securities totaled $408.5 million, including proceeds from a $258.8 million January 2026 offering, funding operations into H2 2028. Q1 2026 net loss was $183.4 million, driven by a $150.0 million in-process R&D charge related to expanding ERAS-0015 license territory to worldwide.
Erasca (Nasdaq: ERAS) announced a clinical trial collaboration and supply agreement with Merck to evaluate ERAS-0015, a pan-RAS molecular glue, with KEYTRUDA (pembrolizumab) in RAS-mutant solid tumors.
The AURORAS-1 proof-of-concept study is sponsored by Erasca, with Merck supplying pembrolizumab at no cost.
Erasca (Nasdaq: ERAS) will present at the Bank of America Securities 2026 Health Care Conference in Las Vegas. Management will take part in a fireside chat on Wednesday, May 13, 2026 at 3:00 pm PT and hold one-on-one investor meetings.
A live audio webcast will be available at Erasca.com/events, with an archived replay accessible for 30 days after the webcast.
Erasca (Nasdaq: ERAS) announced positive preliminary Phase 1 dose escalation data for pan-RAS molecular glue ERAS-0015 in RAS-mutant solid tumors on April 27, 2026. Key points: PAD 16–32 mg QD; selected RDEs 24 mg and 32 mg QD; robust uORRs in KRAS G12X NSCLC (62% 2L+, 75% post-ICI/platinum) and PDAC (40% 2L); favorable safety with no DLTs as of DCO; PK dose-dependent to MAD 40 mg QD. Monotherapy expansion and combo cohorts data expected H1 2027.
Erasca (Nasdaq: ERAS) will host a conference call and live webcast on April 27, 2026 at 4:30 PM ET to discuss preliminary Phase 1 dose-escalation data for its pan-RAS molecular glue ERAS-0015 in patients with RAS-mutant solid tumors.
Investors can join via webcast at Erasca.com/events or by phone (1-877-407-3982 U.S./Canada; 1-201-493-6780 international).